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abstract: Recent studies report the production and isolation of a stable bioactive recombinant human bone morphogenetic protein 15
(rhBMP15) that is appropriately processed in HEK-293 cells and activates the SMAD 1/5/8 pathway in mouse granulosa cell cultures.
Further, the puriﬁed rhBMP15 induces the expression of genes associated with cumulus expansion. Thanks to recent research, we have
a greater understanding of the importance of the dialogue that occurs between the oocyte and the granulosa cell layer with regard to reg-
ulating folliculogenesis and the acquisition of oocyte developmental competence and maturation. BMP15 is one of the critical components of
these intra-follicular communication pathways. The production of recombinant human BMP15 is important for understanding the biochem-
istry of this speciﬁc pathway and for also fully understanding its functional contributions to mediating oocyte development. The production of
a stable recombinant human BMP15 is also important for use in experiments aimed at optimizing ovarian stimulation protocols and in vitro
oocyte maturation methods. This is required to improve oocyte and embryonic developmental competence and increase our ability to effec-
tively use in vitro methods for animal production and the treatment of human infertility.
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Introduction
Controlled ovarian stimulation with gonadotrophins is an important
method of stimulating follicular development, and for collecting more
than the normal numbers of maturing oocytes from a wide variety of
mammalian species (Cantineau et al., 2007; Horcajadas et al., 2007;
Loutradis et al., 2008; Delvigne, 2009; Klemmt et al., 2009; Lussiana
et al., 2009; Verberg et al., 2009). This method has been applied to lit-
erally dozens of species although perhaps most routinely to the
mouse (for research purposes), the cow, sheep and pig (for animal pro-
duction purposes) and the human (for addressing infertility; Cantineau
et al., 2007; Fong et al., 2007; Bell et al., 2008; De Roover et al.,
2008). In all cases, however, the outcome from all ovarian stimulation
protocols is unpredictable. This occurs due to a number of factors
including ovarian cycle synchronization or suppression, ovarian
reserve, subject age and variation in pharmacokinetics between subjects
and genetic factors to name a few (Cantineau et al., 2007; Aboulghar,
2009; Delvigne, 2009; Fauzdar et al., 2009; Figueira et al., 2009;
Klemmt et al., 2009; Raziel et al., 2009; Sismanoglu et al., 2009).
An additional and quite likely a predominant factor that is perhaps
not fully appreciated by all concerned is that the dialogue between the
oocyte and the associated follicle may be suboptimal at the time of
retrieval after gonadotrophin stimulation (Eppig et al., 1997; Eppig,
2001; Matzuk et al., 2002). In fact, the number and quality of the fol-
licles and their oocytes that develop may not be determined by the
hypothalamus and the pituitary, but instead be regulated by
intra-ovarian factors (McNatty et al., 2004). Therefore, to standardize
ovarian stimulation protocols and to achieve reproducible and reliable
outcomes, it will be necessary to ensure the levels of intra-ovarian
factors are optimal and if not, supplement those levels by administer-
ing recombinant peptides.
The study by Li et al. (2009) brings us closer to that goal as they
describe the production and isolation of a stable bioactive recombi-
nant human bone morphogenetic protein 15 (rhBMP15). The
rhBMP15 peptide is appropriately processed in HEK-293 cells and
the puriﬁed protein activates the SMAD 1/5/8 pathway in primary
cultures of mouse granulosa cells. Further, the puriﬁed rhBMP15
induces the expression of genes associated with cumulus expansion,
namely Ptx3, Has2, Tnfaip6 and Ptgs2. Thus, in total, this new puriﬁed
rhBMP15 protein mimics a great number of known BMP15 functions
and represents an important new agent for regulating folliculogenesis
and oocyte developmental competence.
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Intra-ovarian factors
Although the hypothalamic–pituitary–gonadal axis plays an indisputa-
ble and vital role in regulating folliculogenesis, the concerns regarding
the variability in response following the administration of
gonadotrophin-based stimulation protocols extend well beyond the
simple variation in follicle or oocyte numbers (Cantineau et al., 2007;
Horcajadas et al., 2007; De Roover et al., 2008; Loutradis et al., 2008;
Aboulghar, 2009; Fauzdar et al., 2009; Figueira et al., 2009; Verberg
et al., 2009; Vloeberghs et al., 2009). There is an increasing concern
that oocytes generated from ovarian stimulation protocols do not
achieve a normal developmental competence likely due to variations
in oocyte mRNA and protein pools, and possibly due to abnormal vari-
ations in epigenetic patterning (Fauque et al., 2007; Sato et al., 2007;
Meng et al., 2008). Since these components of oocyte developmental
competence are likely inﬂuenced or regulated by intra-ovarian factors,
it may well be necessary to employ recombinant intra-ovarian factors
in combination with gonadotrophins to achieve optimal oocyte devel-
opmental competence in vivo and in vitro.
Growth differentiation factor 9
and BMP15 as key
oocyte-derived factors
Research in recent years has focused on deﬁning the molecular dialo-
gue that occurs between the oocyte and the granulosa cells as the
oocyte grows (Gilchrist et al., 2008). Oocyte paracrine growth
factors acting on neighboring granulosa cells are important regulators
of follicular growth (Eppig, 2001). Attention has primarily focused on
the members of the transforming growth factor-b (TGF-b) family,
including members such as growth differentiation factor 9 (GDF9)
and BMP15. The deletion or mutation of Gdf9 or Bmp15 can greatly
affect fertility (Dong et al., 1996; Galloway et al., 2000). BMP15 null
mice display cumulus cell dysfunction, whereas GDF9 null mice
display failed folliculogenesis (Dong et al., 1996; Yan et al., 2001).
Thus, these factors are not only required for early folliculogenesis,
but they are also potent mediators of granulosa cell differentiation
(Gilchrist et al., 2004a; Juengel and McNatty, 2005; McNatty et al.,
2007). There are important differences between species, e.g. mice
are able to function without BMP15, however this is an essential
factor for both human and sheep fertility (Montgomery et al., 2001;
Yan et al., 2001; Teixeira Filho et al., 2002; McNatty et al., 2003; Di
Pasquale et al., 2004; Hanrahan et al., 2004; Moore et al., 2004;
Dixit et al., 2006). Interestingly, Gdf9 or Bmp15 heterozygosity
results in increased fertility in sheep (Montgomery et al., 2001; Hanra-
han et al., 2004), but once again no obvious effect is observed on
mouse fertility (Dong et al., 1996; Yan et al., 2001). In humans, abnor-
mal expression of GDF9 has been linked to polycystic ovarian syn-
drome (Teixeira Filho et al., 2002), and mutations in Gdf9 and
Bmp15 are associated with premature ovarian failure (Di Pasquale
et al., 2004; Dixit et al., 2006) and dizygotic twinning (Montgomery
et al., 2004; Palmer et al., 2006).
As with all members of the TGF-b family, GDF9 and BMP15 are
produced in a pro-form which is proteolytically processed during syn-
thesis and secretion (Massague´, 1990). This means that the ﬁnal
product consists of an amino-terminal pro-region and a smaller
biologically active carboxy-terminal mature region. A particular charac-
teristic of GDF9 and BMP15 is that they lack the fourth conserved
cysteine residue which is normally present in TGF-b family members
to enable the formation of an inter-monomer disulphide bridge
(McPherron and Lee, 1993; Dube et al., 1998; Laitinen et al., 1998).
Thus, GDF9 and BMP15 form non-covalently associated homodimers
and intriguingly they may be able to form heterodimers in culture (Liao
et al., 2003; McNatty et al., 2003, 2004), which raises the possibility of
greater molecular interactions in vivo. These factors signal via TGF-b
receptors and activate SMAD cascades (Kaivo-oja et al., 2006).
Within the ovary, the granulosa cells express most components of
the TGF-b family signaling system, including type-II receptors and
ALK type-I receptors, co-receptors such as b-glycan, binding proteins
such as follistatin and the SMAD and co-SMAD intracellular messen-
gers (Juengel and McNatty, 2005; Kaivo-oja et al., 2006). Clearly,
GDF9 and BMP15 are among the most important intra-ovarian
factors as their roles in mediating oocyte–granulosa cell interactions
during folliculogenesis would indicate. It is thus critical that we
develop molecular tools that will enable a full understanding of their
biochemistry and function.
Recombinant GDF9 and BMP15
GDF9 was the ﬁrst of these two oocyte-secreted factors to be pro-
duced as a recombinant protein (Elvin et al., 1999; Hayashi et al.,
1999). However, neither of these two reports were the recombinant
protein puriﬁed, being used in various bioassays as an impure prep-
aration. This situation, and the fact that impure preparations have
been used throughout the published literature (Elvin et al., 1999;
Hayashi et al., 1999; Kaivo-Oja et al., 2003, 2005; Gilchrist et al.,
2004b; Hickey et al., 2005; McNatty et al., 2005a, b), may well be
the prime cause for the differing results that have been reported
over the years concerning the bioactivity of GDF9 (Elvin et al.,
1999; Dragovic et al., 2005). Indeed, only in 2008, the characterization
of a puriﬁed recombinant GDF9 has been published (Mottershead
et al., 2008). There have also been sporadic reports of the use of a
puriﬁed commercially available bacterially produced GDF9 (Martins
et al., 2008; Huang et al., 2009; Shi et al., 2009). The issue with any
bacterially produced TGF-b family member is the question of what
percentage of the refolded protein is correctly folded to give biologi-
cally active protein. Further, a bacterially produced protein will lack
post-translational modiﬁcations, such as glycosylation and phosphoryl-
ation, which are of particular relevance for BMP15 and GDF9
(McMahon et al., 2008; Saito et al., 2008). Hence, any bacterially pro-
duced GDF9 or BMP15 should preferably be compared with a puriﬁed
mammalian cell produced version of the protein, before being conﬁ-
dent of having a correctly folded protein with full bioactivity.
The puriﬁcation and initial characterization of a recombinant BMP15
were ﬁrst published in 2000 by the Shimasaki laboratory (Otsuka et al.,
2000). This material was a version of the human BMP15 protein with a
carboxy-terminal FLAG tag, instrumental for the puriﬁcation of the
protein via immunoafﬁnity chromatography. However, as pointed
out by Li et al. (2009), there has been a concern over the effect of
the carboxy-terminal FLAG tag on BMP15 protein stability and bioac-
tivity, as previously it has been found that a carboxy-terminal tag fused
to TGF-b (Wakeﬁeld et al., 1991), or GDF9 (Mottershead et al.,
2008) is detrimental for bioactivity. The recombinant human BMP15
2 Mottershead and Watson
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
produced by Di Pasquale and associates (Di Pasquale et al., 2004;
Bodin et al., 2007; Rossetti et al., 2009) also suffers from the same
issue; in this case, the carboxy-terminal tag is even longer, consisting
of both the Myc and His6 tags in tandem. The new report from the
Matzuk laboratory (Li et al., 2009) has placed the afﬁnity puriﬁcation
tag (in this case, the FLAG tag) close to the amino-terminus of the
mature region of hBMP15, leaving the carboxy-terminus unmodiﬁed.
Further, and most importantly, in this current study, the authors
have compared their puriﬁed N-FLAG tagged hBMP15 with a recently
commercially available untagged hBMP15 mature region. Hence, we
can be conﬁdent that the bioactivity of the epitope-tagged growth
factor represents that also of the untagged native sequence growth
factor. The effect of an epitope tag on the bioactivity of both
human and mouse GDF9 has been clearly described previously
(Mottershead et al., 2008).
Apart from one recent study (McIntosh et al., 2008), the issue of
the role/effect of the pro-region of BMP15 or GDF9 on the bioactivity
of the corresponding mature region is yet to be tackled by the workers
in this ﬁeld. Within the TGF-b family, the effect of the pro-region on
the bioactivity of the corresponding mature region covers the full spec-
trum from potentiation (AMH/MIS; Wilson et al., 1993) to no effect
(BMP9; Brown et al., 2005) to inhibition (TGF-b; McMahon et al.,
1996). This is why it will be important to determine the situation
for GDF9 and BMP15, by comparing the bioactivity of the puriﬁed
(under native conditions) pro-mature complex for each growth
factor with that of the corresponding puriﬁed mature region. Cur-
rently, commercially available mammalian cell produced forms of
mGDF9 and hBMP15 contain just the mature regions of the respective
proteins. Therefore, data based solely on experiments using these
proteins should be interpreted cautiously given that we do not
know how the pro-region affects the bioactivity of the mature
region. To date, all the published, well-characterized puriﬁed recombi-
nant BMP15 proteins (Saito et al., 2008; Li et al., 2009) have contained
both the pro-region as well as the mature region. The situation for the
published recombinant GDF9s (Elvin et al., 1999; Hayashi et al., 1999;
Kaivo-Oja et al., 2003, 2005; Gilchrist et al., 2004b; Liao et al., 2004;
Hickey et al., 2005; McNatty et al., 2005a, b) is most likely to be
similar, although one study has produced and characterized the puri-
ﬁed GDF9 mature region (Mottershead et al., 2008), and a
side-by-side comparison with a pro-mature complex awaits future
studies.
In the current study by Li et al. (2009), the puriﬁed rhBMP15
protein induces the expression of a number of genes in mural granu-
losa cells, a subset of which are associated with cumulus expansion,
namely Ptx3, Has2, Tnfaip6 and Ptgs2. This raises the issue of the invol-
vement of GDF9 and BMP15 in the process of cumulus expansion, a
controversial area where differing results have been obtained by
groups using their own versions of unpuriﬁed (Elvin et al., 1999) or
partially puriﬁed (Dragovic et al., 2005; Dragovic et al., 2007) recom-
binant GDF9, as well as one study using a puriﬁed BMP15 (Yoshino
et al., 2006). Although any extensive discussion as to the nature of
the cumulus cell expansion enabling factor (CEEF) is beyond the
scope of this review, it is hoped that now with the availability of pur-
iﬁed recombinant BMP15 and GDF9 (Li et al., 2009; Sugiura et al.,
2009) that some of the issues surrounding the identity of the CEEF
(Pangas and Matzuk, 2005) will be addressed. A further issue that
should be investigated now that these proteins are available is the
presence or absence of various post-translational modiﬁcations on
the recombinant BMP15 and GDF9 proteins, both of which recently
have been reported to be phosphorylated (McMahon et al., 2008).
This modiﬁcation is crucial to investigate further, as it is the ﬁrst
time that any member of the TGF-b family has been reported to be
phosphorylated, and further, it was stated that this particular modiﬁ-
cation was necessary for biological activity.
BMP15 and GDF9 as reagents for
in vitro oocyte maturation
In vitro oocyte maturation has been employed for producing preim-
plantation embryos from predominantly agricultural species (cow,
sheep, goat and pig) for over 25 years. It is now increasingly being
employed as a method to treat human infertility. The main, well-
documented concern with this approach is that embryos produced
from oocytes matured in vitro display a reduced developmental
capacity than embryos produced from in vivo matured oocytes
(Banwell and Thompson, 2008; Duranthon et al., 2008; Rinaudo and
Lamb, 2008; Watkins et al., 2008; Watkins and Fleming, 2009;
Wells et al., 2009). At the molecular level, variations in gene
expression patterns and abnormalities in epigenetic programming
are increasingly being documented in embryos and fetuses derived
from oocytes matured in vitro (Banwell and Thompson, 2008;
Duranthon et al., 2008; Rinaudo and Lamb, 2008; Watkins et al.,
2008; Watkins and Fleming, 2009; Wells et al., 2009). Our under-
standing of the reasons for these differences in embryos produced
from in vitro and in vivo matured oocytes is rudimentary at best but
likely lies in important variations in the environment in which the
oocyte develops. The most obvious difference is that in vitro
matured oocytes are removed from the follicular environment and
are therefore likely missing or are underexposed to the critical
intra-ovarian factors that control the acquisition of oocyte develop-
mental competence (Banwell and Thompson, 2008; Duranthon
et al., 2008; Rinaudo and Lamb, 2008; Watkins et al., 2008;
Watkins and Fleming, 2009; Wells et al., 2009).
Recent studies have indicated that the addition of BMP15 (Hussein
et al., 2006) or GDF9 (Hussein et al., 2006; Yeo et al., 2008) increases
developmental competence when added within an in vitro maturation
setting. In particular, Yeo et al. (2008) demonstrated that addition of
GDF9 to oocyte in vitro culture medium has a dramatic effect on the
number of day 15 mouse fetuses, indicating that if the oocyte is in
good shape at the start of the procedure, the chances of obtaining
a viable and healthy pregnancy increase as well. This beneﬁcial effect
on the fetal development rate by supplementing in vitro oocyte
culture medium with ovarian paracrine factors is quite likely to apply
to BMP15 supplementation as well, given the effect of BMP15 on
the blastocyst rate and quality (Hussein et al., 2006). However, a limit-
ation of both of these studies (Hussein et al., 2006; Yeo et al., 2008) is
that they involved the use of only partially puriﬁed recombinant
BMP15 and GDF9, and it is very likely that some of the beneﬁcial
effects of GDF9 and BMP15 have been masked by inhibitory com-
ponents from the 293H cell conditioned media.
Thus, the production of a puriﬁed recombinant human BMP15 will
allow for studies aimed at optimizing in vitro oocyte maturation proto-
cols. The expected beneﬁts include an increase in oocyte
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developmental competence, improved embryo quality and pregnancy
rates following embryo transfer, and likely even increased fetal viability.
Conclusions
In the past 10 years, research has revealed great insight into the dia-
logue that occurs between the oocyte and the granulosa cell layer,
raising our understanding of the importance of paracrine and autocrine
intra-ovarian factors in regulating folliculogenesis and acquisition of
oocyte-developmental competence and maturation. BMP15 is one
of the critical components of these intra-follicular communication
pathways. The production of recombinant human BMP15 will afford
an important opportunity to investigate the biochemistry of this
speciﬁc pathway and will provide an opportunity to fully understand
its functional contributions to mediating oocyte development. In
addition, the production of a stable recombinant human BMP15 pro-
vides an important agent for experiments aimed at optimizing ovarian
stimulation and in vitro oocyte maturation protocols. Such optimization
should provide for improved embryo developmental competence and
increase our ability to use in vitro methods for increasing animal pro-
duction and the treatment of human infertility. Finally, the production
of recombinant BMP15 will allow for experiments aimed at rescuing
follicular defects in BMP15 null mice as a prelude to demonstrating
the therapeutic value that recombinant BMP15 could have on the
health of human patients.
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